Sulggi Lee, MD, PhD

Headshot of Sulggi Lee
User Profile Photo

Sulggi Lee, MD, PhD

User Profile Name
CFAR Bioinformatics Subcore Co-Director
Associate Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Career Overview

Dr. Lee's career goals are to better understand the association between host genetics and the host immune response to HIV disease using novel genetic and immunologic translational research methods. Specifically, she is interested in 1) understanding the role of host genetics in determining important immunologic markers in HIV disease, e.g., measures of indoleamine 2,3-dioxygenase (IDO) expression in activated monocytes in chronic HIV; and 2) determining the molecular mechanisms by which the innate immune system responds to HIV, e.g., by analyzing gene expression array data in relation to flow cytometry and metabolomics data among specific HIV-infected populations: HIV elite controllers, HIV-suppressed responders, ARV non-responders.

Spotlight: 2018 CFAR Excellence Award Recipient

After graduating from Stanford University, Dr. Lee went on to receive an MD/PhD at the University of Southern California. She has lived in the Bay Area since the third grade though she was born in Naperville, IL, and spent a few years in Sandy, UT. She returned to Stanford for her internal medicine training, followed by an Infectious Disease fellowship at UCSF.

Her impressive training has launched a quickly accelerating career. Her most recent findings set the stage for her next steps, identifying therapeutic approaches to HIV eradication that would combine practical clinical approaches (early HIV treatment) with novel therapeutic target discovery (e.g., host-HIV genetic omics approaches) to potentially apply towards future HIV eradication strategies.

Lee is now working to merge the two studies presented at this conference: 1) a phase IV trial providing immediate antiretroviral therapy to new, acute HIV-infected individuals and following them over time; and 2) a study that will determine whether timing of ART initiation influences where and how frequently HIV integrates into the host genome, potentially influence HIV latency.

When asked how she would define her ultimate achievement in the field of HIV, Lee says contributing to novel and widespread treatments that improve morbidity/mortality in a large number of HIV-infected individuals, is her long-term goal. And contributing, she adds of course, “to an HIV cure.”

User Profile Bio

Displaying 1 - 25 of 46

  1. Yin K, Peluso MJ, Thomas R, Shin MG, Neidleman J, Luo X, Hoh R, Anglin K, Huang B, Argueta U, Lopez M, Valdivieso D, Asare K, Ibrahim R, St?ndker L, Lu S, Goldberg SA, Lee SA, Lynch KL, Kelly JD, Martin JN, M?nch J, Deeks SG, Henrich TJ, Roan NR. Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. bioRxiv. 2023 Feb 10.
  2. Dwivedi AK, Siegel DA, Thanh C, Hoh R, Hobbs KS, Pan T, Gibson EA, Martin J, Hecht F, Pilcher C, Milush J, Busch MP, Stone M, Huang ML, Levy CN, Roychoudhury P, Hladik F, Jerome KR, Henrich TJ, Deeks SG, Lee SA. Differences in expression of tumor suppressor, innate immune, inflammasome, and potassium/gap junction channel host genes significantly predict viral reservoir size during treated HIV infection. bioRxiv. 2023 Jan 12.
  3. Siegel DA, Thanh C, Wan E, Hoh R, Hobbs K, Pan T, Gibson EA, Kroetz DL, Martin J, Hecht F, Pilcher C, Martin M, Carrington M, Pillai S, Busch MP, Stone M, Levy CN, Huang ML, Roychoudhury P, Hladik F, Jerome KR, Kiem HP, Henrich TJ, Deeks SG, Lee SA. Host variation in type I interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict viral reservoir size. AIDS. 2023 Mar 01; 37(3):477-488.
  4. Xie G, Moron-Lopez S, Siegel DA, Yin K, Polos A, Cohen J, Greenblatt RM, Tien PC, Lee SA, Yukl SA, Roan NR. Common and Divergent Features of T Cells from Blood, Gut, and Genital Tract of Antiretroviral Therapy-Treated HIV+ Women. J Immunol. 2022 04 01; 208(7):1790-1801.
  5. George AF, Luo X, Neidleman J, Hoh R, Vohra P, Thomas R, Shin MG, Lee MJ, Blish CA, Deeks SG, Greene WC, Lee SA, Roan NR. Deep Phenotypic Analysis of Blood and Lymphoid T and NK Cells From HIV+ Controllers and ART-Suppressed Individuals. Front Immunol. 2022; 13:803417.
  6. Neidleman J, Luo X, McGregor M, Xie G, Murray V, Greene WC, Lee SA, Roan NR. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. Elife. 2021 10 12; 10.
  7. Ma T, Ryu H, McGregor M, Babcock B, Neidleman J, Xie G, George AF, Frouard J, Murray V, Gill G, Ghosn E, Newell EW, Lee SA, Roan NR. Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells during Convalescence. J Immunol. 2021 09 01; 207(5):1344-1356.
  8. Neidleman J, Luo X, McGregor M, Xie G, Murray V, Greene WC, Lee SA, Roan NR. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. bioRxiv. 2021 Jul 29.
  9. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, Murray V, Gill G, Greene WC, Vasquez J, Lee SA, Ghosn E, Lynch KL, Roan NR. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell Rep. 2021 07 20; 36(3):109414.
  10. McGinnis CS, Siegel DA, Xie G, Hartoularos G, Stone M, Ye CJ, Gartner ZJ, Roan NR, Lee SA. No detectable alloreactive transcriptional responses under standard sample preparation conditions during donor-multiplexed single-cell RNA sequencing of peripheral blood mononuclear cells. BMC Biol. 2021 01 20; 19(1):10.
  11. Neidleman J, Luo X, Frouard J, Xie G, Gill G, Stein ES, McGregor M, Ma T, George AF, Kosters A, Greene WC, Vasquez J, Ghosn E, Lee S, Roan NR. SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential. Cell Rep Med. 2020 Sep 22; 1(6):100081.
  12. Hsiao F, Frouard J, Gramatica A, Xie G, Telwatte S, Lee GQ, Roychoudhury P, Schwarzer R, Luo X, Yukl SA, Lee S, Hoh R, Deeks SG, Jones RB, Cavrois M, Greene WC, Roan NR. Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection. PLoS Pathog. 2020 04; 16(4):e1008450.
  13. Lee SA, Telwatte S, Hatano H, Kashuba ADM, Cottrell ML, Hoh R, Liegler TJ, Stephenson S, Somsouk M, Hunt PW, Deeks SG, Yukl S, Savic RM. Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. J Acquir Immune Defic Syndr. 2020 04 15; 83(5):530-537.
  14. Gong J, Noel S, Hsu J, Bush EL, Arend LJ, Sadasivam M, Lee SA, Kurzhagen JT, Hamad ARA, Rabb H. TCR+CD4-CD8- (double negative) T cells protect from cisplatin-induced renal epithelial cell apoptosis and acute kidney injury. Am J Physiol Renal Physiol. 2020 06 01; 318(6):F1500-F1512.
  15. M. Peluso, P. Burbelo, S. Kumar, S. Munter, R. Hoh, S. Lee, P. Hunt, R. Rutishauser, T. Henrich, S. Deeks. OP 4.2 Characterising ‘exceptional’ control among HIV elite controllers. Journal of virus eradication. 2019 Dec 1; 5:31.
  16. S. Lee, K. Kesmy, P. Bacchetti, R. Hoh, J. Lifson, D. Cary, B. Peterlin, S. Deeks, D. Hartigan-O’Connor. 20 Kansui, an ingenol-containing herbal supplement, safely induced CD8, NK, and monocyte activation in three ART-suppressed SIVmac251-infected rhesus macaques. Journal of virus eradication. 2019 Jul 1; 5:12-13.
  17. M. Peluso, P. Burbelo, S. Kumar, S. Munter, R. Hoh, S. Lee, P. Hunt, R. Rutishauser, T. Henrich, S. Deeks. OP 4.2 Characterising ‘exceptional’ control among HIV elite controllers. Journal of virus eradication. 2019 Dec 1; 5:31.
  18. S. Lee, K. Kesmy, P. Bacchetti, R. Hoh, J. Lifson, D. Cary, B. Peterlin, S. Deeks, D. Hartigan-O’Connor. 20 Kansui, an ingenol-containing herbal supplement, safely induced CD8, NK, and monocyte activation in three ART-suppressed SIVmac251-infected rhesus macaques. Journal of virus eradication. 2019 Jul 1; 5:12-13.
  19. Cohen SE, Sachdev D, Lee SA, Scheer S, Bacon O, Chen MJ, Okochi H, Anderson PL, Kearney MF, Coffey S, Scott H, Grant RM, Havlir D, Gandhi M. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2018 Nov 29.
  20. Telwatte S, Lee S, Somsouk M, Hatano H, Baker C, Kaiser P, Kim P, Chen TH, Milush J, Hunt PW, Deeks SG, Wong JK, Yukl SA. Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency. PLoS Pathog. 2018 Nov; 14(11):e1007357.
  21. Lee SA, Elliott JH, McMahon J, Hartogenesis W, Bumpus NN, Lifson JD, Gorelick RJ, Bacchetti P, Deeks SG, Lewin SR, Savic RM. Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. Clin Pharmacol Ther. 2018 Aug 23.
  22. Chang JL, Lee SA, Tsai AC, Musinguzi N, Muzoora C, Bwana B, Boum Y, Haberer JE, Hunt PW, Martin J, Bangsberg DR, Kroetz DL, Siedner MJ. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies. AIDS Res Hum Retroviruses. 2018 Nov; 34(11):982-992.
  23. Lee SA, Elliott JH, McMahon J, Hartogenesis W, Bumpus NN, Lifson JD, Gorelick RJ, Bacchetti P, Deeks SG, Lewin SR, Savic RM. Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. Clin Pharmacol Ther. 2019 03; 105(3):692-702.
  24. S. Lee, K. Haworth, T. Henrich, S. Deeks, H.P. Kiem. PP4.10 HIV integrates in genes regulating cell cycle, DNA damage, and viral transport. Journal of virus eradication. 2017 Dec 1; 3:26.
  25. Chang JL, Lee SA, Tsai AC, Musinguzi N, Muzoora C, Bwana B, Boum Y, Haberer JE, Hunt PW, Martin J, Bangsberg DR, Kroetz DL, Siedner MJ. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies. AIDS Res Hum Retroviruses. 2018 11; 34(11):982-992.